Sudeep Pharma (NSE:SUDEEPPHRM) Piotroski F-Score: N/A (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SUDEEPPHRM Sudeep Pharma Ltd NSE:SUDEEPPHRM
21 GF Score
Price ₹1,155.00
! 8 Warning Signs
View Full Analysis

What is Sudeep Pharma Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sudeep Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sudeep Pharma's Piotroski F-Score or its related term are showing as below:

Sudeep Pharma  (NSE:SUDEEPPHRM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sudeep Pharma Piotroski F-Score Related Terms


Sudeep Pharma Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sudeep Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma Piotroski F-Score Chart

Sudeep Pharma Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
- 5.00 7.00 5.00 4.00

Sudeep Pharma Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial - - - 4.00 -

NSE:SUDEEPPHRM vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sudeep Pharma Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sudeep Pharma's Piotroski F-Score falls into.


NSE:SUDEEPPHRM
21GF Score
Sudeep Pharma Ltd NSE:SUDEEPPHRM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹1,729 Mil.
Cash Flow from Operations was ₹616 Mil.
Revenue was ₹6,388 Mil.
Gross Profit was ₹3,169 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (7191.927 + 11776.179) / 2 = ₹9484.053 Mil.
Total Assets at the begining of this year (Mar25) was ₹7,192 Mil.
Long-Term Debt & Capital Lease Obligation was ₹356 Mil.
Total Current Assets was ₹6,240 Mil.
Total Current Liabilities was ₹2,020 Mil.
Net Income was ₹1,387 Mil.

Revenue was ₹4,974 Mil.
Gross Profit was ₹2,569 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (5158.834 + 7191.927) / 2 = ₹6175.3805 Mil.
Total Assets at the begining of last year (Mar24) was ₹5,159 Mil.
Long-Term Debt & Capital Lease Obligation was ₹412 Mil.
Total Current Assets was ₹4,241 Mil.
Total Current Liabilities was ₹1,748 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sudeep Pharma's current Net Income (TTM) was 1,729. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sudeep Pharma's current Cash Flow from Operations (TTM) was 616. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1728.926/7191.927
=0.24039816

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1387.292/5158.834
=0.26891581

Sudeep Pharma's return on assets of this year was 0.24039816. Sudeep Pharma's return on assets of last year was 0.26891581. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sudeep Pharma's current Net Income (TTM) was 1,729. Sudeep Pharma's current Cash Flow from Operations (TTM) was 616. ==> 616 <= 1,729 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=356.229/9484.053
=0.03756084

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=412.084/6175.3805
=0.06673014

Sudeep Pharma's gearing of this year was 0.03756084. Sudeep Pharma's gearing of last year was 0.06673014. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=6239.66/2019.625
=3.08951414

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4241.204/1747.569
=2.42691648

Sudeep Pharma's current ratio of this year was 3.08951414. Sudeep Pharma's current ratio of last year was 2.42691648. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sudeep Pharma's number of shares in issue this year was 0. Sudeep Pharma's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3168.896/6388.014
=0.49606904

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2569.489/4974.078
=0.51657594

Sudeep Pharma's gross margin of this year was 0.49606904. Sudeep Pharma's gross margin of last year was 0.51657594. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=6388.014/7191.927
=0.88822008

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=4974.078/5158.834
=0.96418648

Sudeep Pharma's asset turnover of this year was 0.88822008. Sudeep Pharma's asset turnover of last year was 0.96418648. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sudeep Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.


Sudeep Pharma Business Description

Other Exchanges 544619:India
Address Gotri-Sevasi Road, 601-602, 6th floor, Sears II, East Wing, Towers - 2, Sevasi, Vadodara, GJ, IND, 391101
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
21GF Score

Get the complete analysis for NSE:SUDEEPPHRM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,155.00
Price